Table 1.
Details of the horse serum samples used in this study.
| WNV strain or vaccine | Sample group number | Infection mode | Nº of serum samples | Nº of animals | dpi/dpv | Source/origin | Confirmatory test |
|---|---|---|---|---|---|---|---|
| Experimental | |||||||
| Israel '98 (L1) | A1 | Experimental | 8 | 1 | 0-58 | France | IgG,IgM,VNT |
| Austria '08 (L2) | A1 | Experimental | 8 | 1 | 0-58 | France | IgG,IgM,VNT |
| Equip W N V a | B1 | Vaccine (experimental) | 50 | 5 | 0-115 | Spain | |
| Field | |||||||
| Unknown | A2 | Natural | 22 | 22 | France | IgG, IgM | |
| ＇＇ | A3 | Natural | 17 | 17 | Italy | IgM | |
| ＇＇ | A4 | Natural | 24 | 24 | Morocco | IgM,IgG | |
| ＇＇ | A5 | Natural | 52 | 52 | Spain | IgM, VNT | |
| Equip W N V a | B2 | Vaccine | 26 | 26 | Spain | ||
| Proteq WNV 1xb | B3 | Vaccine | 30 | 30 | Spain | ||
| Proteq WNV2xb | B4 | Vaccine | 76 | 76 | Spain | ||
| WNVVa c c | B5 | Vaccine | 13 | 13 | Morocco | ||
| Recombite k d + WNVac | B6 | Vaccine | 19 | 19 | Morocco | ||
| None | C | Field (no exposure to WNV) | 96 | 96 | Spain |
a. Duvaxyne WNV (called now Equip WNV) commercially available by Zoetis. Inactivated WNV, strain VM-2 injectable. Administration route 2 doses IM/annual recalled.
b. Proteq WNV commercially available by Merial. Recombinant virus canary pox containing PrM-E WNV proteins. Administration route 2 doses IM/annual recalled.
c. WNV Vac commercially available by Biopharma. Inactivated WNV, strain Maroc 96-107 injectable. Administration route 2 doses IM/annual recalled.
d. Recombitek equine WNV. The same vaccine as Proteq WNV (b) but lyophilized presentation.